Member Info for BurtonD

"We are delighted to announce this successful institutional placing. This significant increase in their investment by well-known UK institutions is a testimony tof the quality of our assets, our team and the progress we have made and will continue to make as we not only start production but focus on post production activities like sales, marketing and expansion. The proceeds will be used primarily to meet the working capital needs of our operations at the Gravelotte Emerald Mine once production has commenced and is expected to take us through to first revenue."

https://www.londonstockexchange.com/news-article/URAH/issue-of-equity/16349763

Oxford Cannabinoid Technologies Holdings plc (LSE:OCTP), the biotech company developing prescription cannabinoid medicines, announces that it has been informed that Clarissa Sowemimo-Coker, the Chief Executive Officer of the Company, and Julie Pomeroy, the Company's Non-Executive Chair, have today purchased ordinary shares of £0.001 ("Ordinary Shares") in the Company.

Recent raise was .5 remember

https://www.londonstockexchange.com/news-article/OCTP/directors-dealings/16349345

Https://www.londonstockexchange.com/news-article/LEX/drilling-update/16347680

Ed Nealon, Lexington Gold's Chairman, commented:

"These latest developments from our Bothaville Project drilling campaign are highly encouraging. The completion of two diamond drill holes intersecting the A-Reef and showcasing signs of mineralisation, brings us closer to realising the potential of this project.

"These preliminary findings also serve to validate our strategic approach to exploring the Kimberley Formation and highlight the untapped opportunities within our South African portfolio. We remain committed to advancing our exploration efforts and look forward to providing further updates as our ongoing programme progresses."

How about a premium stake from a stategic investor?

Wow...imagine that....

Great news this just after CEO (Cathal Friel) bought again recently of course...

22 February 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification that on 21 February 2024, Jeremy Skillington, Chief Executive Officer of the Company, purchased 154,764 ordinary shares at a price of 10.8 pence per share (the "Purchase").

Following the Purchase, Jeremy holds 873,497 ordinary shares representing approximately 0.17 per cent of the Company's issued share capital.

Https://youtu.be/G4sJEHN8Nxo

Https://youtu.be/7FYt3YpgoXs

“…Anything that we own is for sale at the right price, in the right circumstances of course. We’re seeing a huge amount of deal flow and we’ve come very, very close to making some investments…”

INTERVIEW LINK ONLY :

https://youtu.be/A_WH5IBt7Ko

FULL ARTICLE PLUS INTERVIEW LINK :

https://total-market-solutions.com/2024/02/seed-innovations-ltd-feb-2024/

“…We’re in production. We’re making profit. We pay dividends and share buybacks. Everything is absolutely good. All I’m interested in is profit…”

https://total-market-solutions.com/2024/02/union-jack-oil-plc-feb-2024/

Cathal Friel, Executive Chairman of the Company, purchased 830,000 ordinary shares at a price of 11.68 pence per share

Following the Purchase, Cathal holds 37,219,757 ordinary shares representing approximately 7.4 per cent of the Company's issued share capital.

https://www.londonstockexchange.com/news-article/POLB/director-share-purchase/16339234

They have highlighted this on their social media:

https://twitter.com/PoolbegPharma/status/1758446020168491467

"As part of my ongoing commitment to the Company, I also intend to start increasing my shareholding in Poolbeg as and when I am able to do so."

https://www.londonstockexchange.com/news-article/POLB/board-role-change-and-launch-of-eip/16333439

Https://www.investorschronicle.co.uk/ideas/2024/02/12/business-is-booming-at-hvivo/

Research conducted on behalf of Poolbeg confirms a > US$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS as an orally delivered preventative therapy.

Cancer immunotherapies have been approved in rare and orphan blood cancers and so the Company can see potential for POLB 001 in one or more of these cancer types.

https://www.londonstockexchange.com/news-article/POLB/market-opportunity-for-polb-001-for-crs/16327313

POLB 001 in cancer immunotherapy-induced CRS will be developed alongside Poolbeg’s existing portfolio of assets including their influenza programme, AI drug discovery programmes and oral delivery of GLP-1 for obesity and other metabolic diseases.

After these significant results, what does the next exciting chapter for ECR Minerals start to feel like ask @TMSreach

“…we’ve got some tax losses that could be quite valuable in the right hands and to others in our space…”

Full article with Video : https://total-market-solutions.com/2024/02/ecr-minerals-plc-feb-2024/

Video Interview only : https://youtu.be/G4sJEHN8Nxo

“…Since making its potentially transformative acquisition URAH has made solid progress towards bringing the mine back into production on a modest budget…”

https://total-market-solutions.com/2024/02/ura-holdings-plc-2/

“…Amryt was a fantastic journey and story. We helped numerous patients worldwide, and the value creation followed and that’s what we’re going to do with Poolbeg…”

Full Article plus interview :

https://total-market-solutions.com/2024/02/poolbeg-pharma-plc-copy/

Interview only :

https://youtu.be/ZF-1MoycuXc

This morning’s interview introducing Laura Maher, the #POLB VP of Clinical Operations:

https://twitter.com/PoolbegPharma/status/1755133379857567838

“…The share price has, however, begun to recover over the past few days, momentum that might be sustained by this week’s confirmation of the Record Date for eligibility for potential proceeds from the claim against the Republic…”

https://total-market-solutions.com/2024/02/ascent-resources-plc-2/

100%

Why sell now?